Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumour Relapse”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04763616
What this trial is testing

Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

Who this might be right for
Natural Killer/T-cell LymphomaRelapsed Natural Killer/T-cell LymphomaRefractory Natural Killer/T-cell Lymphoma
Won Seog Kim 37
Not applicableLooking for participantsNCT07514052
What this trial is testing

Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study

Who this might be right for
Multiple Myeloma of Bone
Shanxi Bethune Hospital 127
Testing effectiveness (Phase 2)WithdrawnNCT01170052
What this trial is testing

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Mantle Cell Lymphoma
Charite University, Berlin, Germany 20
Testing effectiveness (Phase 2)Looking for participantsNCT01804634
What this trial is testing

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Who this might be right for
Refractory and/or Relapsed Metastatic Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 60
Very early researchNot Yet RecruitingNCT06786299
What this trial is testing

Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia(AML)
First Affiliated Hospital of Zhejiang University 18
Testing effectiveness (Phase 2)UnknownNCT04131621
What this trial is testing

Nivolumab/Ipilimumab in Second Line CUP-syndrome

Who this might be right for
Cancer of Unknown Primary Site
University Hospital Heidelberg 194
Testing effectiveness (Phase 2)UnknownNCT04056949
What this trial is testing

Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy

Who this might be right for
Extensive-Stage Small Cell Lung Cancer
Junling Li 30
Testing effectiveness (Phase 2)Ended earlyNCT01685021
What this trial is testing

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Who this might be right for
Acute Lymphoblastic Leukemia
MorphoSys AG 22
Early research (Phase 1)Study completedNCT02594384
What this trial is testing

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
OrphAI Therapeutics 62
Testing effectiveness (Phase 2)Ended earlyNCT02609984
What this trial is testing

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Who this might be right for
SarcomaMyxoid/Round Cell LiposarcomaSynovial Sarcoma+4 more
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 89
Early research (Phase 1)Not Yet RecruitingNCT07841002
What this trial is testing

CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML)
Liping Dou 12
Testing effectiveness (Phase 2)Study completedNCT01295307
What this trial is testing

Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Technische Universität Dresden 86
Early research (Phase 1)Ended earlyNCT00928200
What this trial is testing

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Who this might be right for
Relapsed Acute Lymphoblastic LeukemiaAllergy to PEG e.Coli AsparaginaseAllergy to Native e.Coli Asparaginase
Therapeutic Advances in Childhood Leukemia Consortium 1
Testing effectiveness (Phase 2)Ended earlyNCT01625260
What this trial is testing

ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer
Altor BioScience 12
Testing effectiveness (Phase 2)UnknownNCT04500561
What this trial is testing

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Who this might be right for
Diffuse Large B Cell Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd. 28
Early research (Phase 1)Not Yet RecruitingNCT07692529
What this trial is testing

A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia

Who this might be right for
Large Granular Lymphocyte LeukemiaT-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China 10
Testing effectiveness (Phase 2)Study completedNCT02560337
What this trial is testing

Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.

Who this might be right for
Ovarian Cancer
Vejle Hospital 26
Testing effectiveness (Phase 2)Study completedNCT03701295
What this trial is testing

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement

Who this might be right for
Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLLLeukemia CutisRecurrent Acute Myeloid Leukemia+1 more
National Cancer Institute (NCI) 1
Early research (Phase 1)Ended earlyNCT00848601
What this trial is testing

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Who this might be right for
Prostate CancerNon-Hodgkins Lymphoma
Astex Pharmaceuticals, Inc. 14
Testing effectiveness (Phase 2)Looking for participantsNCT07473167
What this trial is testing

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Who this might be right for
Relapsed Large B-cell LymphomaRefractory Large B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)+3 more
TICAROS Co., Ltd. 98
Next Page